Anavex Life Sciences climbs after Alzheimer's drug trial data
ReutersSep 9, 2025 12:53 PM
** Shares of drug developer Anavex Life Sciences AVXL.O rise 2.7% to $9.60 premarket
** Co says its experimental Alzheimer's drug, blarcamesine, slowed memory loss among early-stage patients after 48 weeks of treatment in mid-to-late stage trial
** Patients who took daily 30 mg dose of blarcamesine in trial showed "barely detectable" decline on key cognitive tests, co says
** Blarcamesine is once-daily oral pill that works by activating protein SIGMAR1 to help clear damaged proteins in brain, slowing cognitive decline in early Alzheimer's patients
** As of last close, stock down 13% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
U.S. August CPI Preview: Persistent Rise in Inflation, What Impact on Rate Cuts? And on US Stocks?
TradingKey - On 11 September 2025, the U.S. will publish August CPI data. Consensus forecasts indicate a 0.3% month-over-month increase for both headline CPI and core CPI. As a result, headline CPI year-over-year may climb to 2.9%, up from 2.7%TradingKey
16 hours ago
Unlocking Gold’s Next Leg: $4,000 in Reach by 2025？
TradingKey - Gold has kicked off a fresh uptrend in early September, breaking out of months of compression and reclaiming key territory. The decisive move above $3,500 establishes a new support base and puts higher objectives back on the table for the weeks aheadTradingKey
Thu, Sep 4
2025 Hottest US IPO Week: Klarna, Gemini, Figure Set for “Triple Launch”
TradingKey - 5 companies are now pricing their U.S. initial public offerings (IPOs) for the week starting September 8, with a total expected fundraising exceeding $3 billion, making it the busiest IPO week of 2025. Investors are closely watching the debut performance of Klarna, Gemini, and Figure.TradingKey
Wed, Sep 3
Lululemon Stock Is Beaten Down Now, But It Could 10X
Key PointsLululemon's revenue growth in North America should turn the corner soon. Its China and other international revenue has a lot of future potential for growth. The stock is trading at a cheap price, with management buying back shares. Recent years have been tough sledding for Lululemon...The Motley Fool
Fri, Jul 4
Tradingkey
